IGF1R and melanoma: Treatment of GCNT2 KD, GCNT2 OE and control melanoma cell variants with IGF-1, the cognate ligand for IGF1R (Fig. 5e), revealed that low GCNT2/I-branched glycan levels increased melanoma cell proliferation (Fig. 5f).